Related Publications

ANTI-INFECTIVES

Covid-19

Casadevall et al, (2020) A randomized trial of convalescent plasma for COVID-19 – Potentially hopeful signalsJAMA  (http://doi.org/doi:10.1001/jama.2020.10218)

Hachim et al, (2020) Beyond the Spike: identification of viral targets of the antibody response to SARS-CoV-2 in COVID-19 patients(https://doi.org/10.1101/2020.04.30.20085670)

Li et al, (2020) Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: A randomized clinical trialJAMA  (http://doi.org/doi:10.1001/jama.2020.10044)

Polio

Kouiavskaia et al. (2020) Universal ELISA for quantification of D-antigen in inactivated poliovirus vaccinesJ Virol Methods  276:113785  (http://doi.org/doi: 10.1016/j.jviromet.2019.113785)

Puligedda et al, (2020) Human IgA Monoclonal Antibodies That Neutralize Poliovirus, Produced by Hybridomas and Recombinant ExpressionAntibodies 9, 5  (http://doi.org/doi:10.3390/antib9010005)

Puligedda et al, (2017) Characterization of human monoclonal antibodies that neutralize multiple poliovirus serotypesVaccine 35, 5455–5462  (http://doi.org/doi:10.1016/j.vaccine.2017.03.038)

Puligedda et al, (2014) Human monoclonal antibodies that neutralize vaccine and wild-type poliovirus strainsAntiviral Res 108, 36–43

ONCOLOGY

B Cells in Oncology

Cabrita et al, (2020) Tertiary lymphoid structures improve immunotherapy and survival in melanoma,  Nature 577:561-565

Helmink et al, (2020) B cells and tertiary lymphoid structures promote immunotherapy responseNature 577:549-555

Petitprez et al, (2020) B cells are associated with survival and immunotherapy response in sarcoma,  Nature 577:556-560

DeFalco et al, (2018) Non-progressing cancer patients have persistent B cell responses expressing shared antibody paratopes that target public tumor antigensClinical Immunology 187:37-45.

Bushey et al, (2016) A therapeutic antibody for cancer, derived from single human B cellsCell Reports  (http://doi.org/doi:10.1016/j.celrep.2016.04.038)